Share on StockTwits
 

Stock analysts at Needham & Company raised their price target on shares of Dyax Corp. (NASDAQ:DYAX) to $13.00 in a report issued on Tuesday, ARN reports. Needham & Company’s price target would indicate a potential upside of 44.77% from the company’s current price.

Separately, analysts at Wedbush initiated coverage on shares of Dyax Corp. in a research note on Monday, January 13th. They set an “outperform” rating and a $11.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $9.60.

Dyax Corp. (NASDAQ:DYAX) opened at 8.98 on Tuesday. Dyax Corp. has a 52-week low of $2.26 and a 52-week high of $9.72. The stock has a 50-day moving average of $8.43 and a 200-day moving average of $6.. The company’s market cap is $1.087 billion.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.